BridgeBio’s BBP-418 Surpasses Phase 3 Milestones, Paving Way for Muscular Dystrophy FDA Submission
- November 5, 2025
Sanofi’s Efdoralprin Alfa Shows Promise in Treating Alpha-1 Antitrypsin Deficiency Emphysema
Merck & Co Launches Phase IIb Trials of Tulisokibart in Rheumatoid Arthritis and Other Inflammatory Diseases
You Are Not Alone: Empowering the Advanced Kidney Cancer Community
LISTEN TO OUR PODCAST
THE LATEST FROM PATIENT WORTHY
FEATURED
UPCOMING EVENTS
SIGN UP FOR OUR NEWSLETTER
BridgeBio’s BBP-418 Surpasses Phase 3 Milestones, Paving Way for Muscular Dystrophy FDA Submission bit.ly/47ygUh6 Read now at PatientWorthy.com
#PatientWorthy #MuscularDystrophy #Limb-GirdleMuscularDystrophy #LGMD2I/R9
Patient Worthy is looking for individuals who are interested in sharing their experiences with Anaphylaxis. Be the reason someone feels seen, supported, and inspired! Ready to share? Click here: bit.ly/4dV7gru
#anaphylaxis #anaphylaxisawareness #foodallergies #epipen #allergicreaction
Primary sclerosing cholangitis (PSC) isn't widely known but awareness can change that! PSC causes scarring in the bile ducts, slowly damaging the liver, often before symptoms even appear. There's no cure yet, but early detection and better understanding can make a big difference! #PSC #rarediseaseoftheweek #raredisease #PatientWorthy
